Generalisability, Transferability, Complexity and Relevance

Evidence-Based Decisions and Economics: Health Care, Social Welfare, Education and Criminal Justice, Second Edition

Volumn , Issue , 2010, Pages 56-66

  Walker, Damian G ^a   Teerawattananon, Yot ^b   Anderson, Rob ^c   Richardson, Gerry ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c UNIVERSITY OF EXETER   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Checklists for assessing generalisability of economic evaluations; Complexity and economic evidence; Factors affecting generalisability population factors; Generalisability and transferability with respect to economic analysis; Generalisability, transferability, complexity and relevance cost effectiveness data; Importance of generalisability for producers, users and funders; Overall incremental cost effectiveness ratio (ICER); Transferability ability to extrapolate results obtained; Transferring economic evaluation data methods

Indexed keywords

EID: 84859762775     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444320398.ch5     Document Type: Chapter

References (47)

1. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK to date. Journal of Health Services Research and Policy 2005; 10: 245-250.
2. Murray CJL, Evans DB, Acharya A, Baltussen RMPM. Development of WHO guidelines on generalized costeffectiveness analysis. Health Economics 2000; 9(3): 235-251.
3. World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Geneva: World Health Organization, 2010. Available from: www.who.int/choice/en/.
4. Tan-Torres Edejer T, Baltussen RMPM, Adam T, et al. (eds). Making Choices in Health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003.
5. Currie G, Manns B. Glossary of terms for health economics and systematic review. In: Donaldson C, Mugford M, Vale L (eds) Evidence-Based Health Economics: from effectiveness to efficiency in systematic review. London: BMJ Books, 2002.
6. Antonanzas F, Rodríguez-Ibeas R, Juárez C, Hutter F, Lorente R, Pinillos M. Transferability indices for health economic evaluations: methods and applications. Health Economics 2009; 18(6): 629-643.
7. Anderson R. New MRC guidance on evaluating complex interventions: clarifying what interventions work by researching how and why they are effective. British Medical Journal 2008; 337(a1937): 944-945.
8. Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex costeffectiveness modelling. Statistics in Medicine 2003; 22(23): 3687-3709.
9. Grieve R, Nixon R, Thompson S, Cairns J. Multilevel models for estimating incremental net benefit in multinational studies. Health Economics 2007; 16(8): 815-826.
10. Manca A, Willan AR. Lost in translation: accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics 2006; 24(11): 1101-1119.
11. Teerawattananon Y, Russell S. A difficult balancing act: policy actors'perspectives on using economic evaluation to inform health-care coverage decisions under the Universal Health Insurance Coverage Scheme in Thailand. Value in Health 2008; 11(suppl 1): S52-S60.
12. Teerawattananon Y, Vos T, Tangcharoensathien V, Mugford M. Cost-effectiveness of models for prevention of vertical HIV transmission-voluntary counseling and testing and choices of drug regimen. Cost Effectiveness and Resource Allocation 2005; 3: 7.
13. Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in health care: a review and case studies. Health Technology Assessment 2004; 8(49): 1-192.
14. Goeree R, Burke N, O'Reilly D, Blackhouse G, Tarride J-E. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Current Medical Research and Opinion 2007; 23(4): 671-682.
15. Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004; 22(13): 857-876.
16. Boulenger S, Nixon J, Drummond M, Ulmann P, Rice S, de Pouvourville G. Can economic evaluations be made more transferable? European Journal of Health Economics 2005; 6(4): 334-346.
17. Teerawattananon Y, Mugford M. Is it worth offering a routine laparoscopic cholecystectomy in developing countries? A Thailand case study. Cost Effectiveness and Resource Allocation 2005; 3: 10.
18. Tarn TY, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004; 10: 5-15.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
20. Sculpher MJ, Drummond MF. Analysis sans frontieres: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics 2006; 24(11): 1087-1099.
21. Kumaranayake L. The real and the nominal? Making inflationary adjustments to cost and other economic data. Health Policy and Planning 2000;15(2): 230-234.
22. Wordsworth S, Ludbrook A. Comparing costing results in across country economic evaluations: the use of technology specific purchasing power parities. Health Economics 2005; 14(1): 93-99.
23. Busse R, Schreyögg J, Smith PC. Variability in health care treatment costs amongst nine EU countries-results from the HealthBASKET project. Health Economics 2008; 17(suppl 1): S1-S8.
24. Schreyögg J, Tiemann O, Stargardt T, Busse R. Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories. Health Economics 2008; 17(suppl 1): S95-S103.
25. Shemilt I, Thomas J, Morciano M. A new web-based tool for adjusting costs to a common currency and price year. Evidence and Policy, in press.
26. Menzin J, Oster G, Davies L, et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. International Journal of Technology Assessment in Health care 1996; 12(1): 52-61.
27. Jonsson B, Weinstein MC. Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb. International Journal of Technology Assessment in Health care 1997; 13(1): 49-58.
28. Shemilt I, Mugford M, Byford S, et al. Incorporating economics evidence. In: Higgins JPT, Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 (updated September 2008). Oxford: Cochrane Collaboration, 2008.
29. Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Statistics in Medicine 2003; 22(12): 1955-1976.
30. Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Economics 2005;1 4(5): 471-485.
31. Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. International Journal of Technology Assessment in Health care 2005; 21(2): 165-171.
32. Birch S. As a matter of fact: evidence-based decision-making unplugged. Health Economics 1997; 6(6): 547-559.
33. Birch S, Gafni A. Evidence-based health economics. Answers in search of questions? In: Kristiansen IS, Mooney G (eds) Evidence-Based Medicine in Its Place. Adington: Routledge, 2004.
34. Birch S, Gafni A. Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results. Health Policy 2003; 64(2): 207-219.
35. MRC Health Services and Public Health Research Board. A Framework for the Development and Evaluation of RCTs for Complex Interventions to Improve Health. London: Medical Research Council, 2000.
36. Hawe P, Shiell A, Riley T. Complex interventions: how far 'out of control'should a randomised controlled trial be? British Medical Journal 2004; 328(7455): 1562-1563.
37. Hawe P, Shiell A, Riley T, Gold L. Methods for exploring implementation variation and local context within a cluster-randomised community intervention trial. Journal of Epidemiology and Community Health 2004; 58(9): 788-793.
38. Oakley A, Strange V, Bonell C, Allen E, Stephenson J. Process evaluation in randomised controlled trials of complex interventions. British Medical Journal 2007; 332(7538): 413-416.
39. Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review-a new method of systematic review designed for complex policy interventions. Journal of Health Services Research and Policy 2005; 10(suppl 1): S1:21-S1:34.
40. Byford S, Sefton T. Economic evaluation of complex health and social care interventions. National Institute Economic Review 2003; 186(1): 98-108.
41. Shiell A, Hawe P, Gold L. Complex interventions or complex systems? Implications for health economic evaluations. British Medical Journal 2008; 336(7656): 1281-1283.
42. Medical Research Council. Developing and Evaluating Complex Interventions: new guidance. London: Medical Research Council, 2008.
43. Jackson N, Waters E, for the Guidelines for Systematic Reviews in Health Promotion and Public Health Taskforce. Criteria for the systematic review of health promotion and public health interventions. Health Promotion International 2005; 20(4): 367-374.
44. Petticrew M, Roberts H. Systematic Reviews in the Social Sciences: a practical guide. Malden: Blackwell Publishing, 2006.
45. Richardson G. Cost-effectiveness of interventions to support self care. PhD thesis. York: University of York, 2008.
46. Chinnock P, Siegfried N, Clarke M. Is evidence-based medicine relevant to the developing world? PLoS Medicine 2005; 2(5): e107.
47. Centre for the Evaluation of Value and Risk in Health. CEA Registry. Boston: Tufts Medical Center, 2010. Available from: https://research.tufts-nemc.org/cear/Default.aspx.